The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus

The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus

Abstract Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor that reduces blood glucose, as well as blood pressure, body weight, and albuminuria in patients with type 2 diabetes mellitus (T2DM). In the CANagliflozin cardioVascular Assessment Study (CANVAS) Program, patients with T2D...

Full description

Bibliographic Details
Main Authors: Salvatore Carbone, Dave L. Dixon
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Cardiovascular Diabetology
Subjects:
Diabetes mellitus
Major adverse cardiovascular event
Sodium glucose co-transporter 2 inhibitor
Canagliflozin
Online Access:http://link.springer.com/article/10.1186/s12933-019-0869-2

Internet

http://link.springer.com/article/10.1186/s12933-019-0869-2

Similar Items